Is ARAY or APYX more profitable?

Accuray has a net margin of -12.24% compared to Apyx Medical's net margin of -14.78%. Apyx Medical's return on equity of -76.60% beat Accuray's return on equity. Company Net Margins Return on Equity Return on Assets Accuray -12.24% -97.85% -10.82% Apyx Medical -14.78% -76.60% -13.91%

Does the media prefer ARAY or APYX?

In the previous week, Apyx Medical had 2 more articles in the media than Accuray. MarketBeat recorded 3 mentions for Apyx Medical and 1 mentions for Accuray. Apyx Medical's average media sentiment score of 0.85 beat Accuray's score of 0.68 indicating that Apyx Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apyx Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, LNSR or ARAY?

LENSAR has higher earnings, but lower revenue than Accuray. LENSAR is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.73 -$34.28M -$0.33 N/A Accuray $401.95M 0.08 -$49.19M -$0.40 N/A

Is LNSR or ARAY more profitable?

LENSAR has a net margin of 57.57% compared to Accuray's net margin of -12.24%. Accuray's return on equity of -97.85% beat LENSAR's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% Accuray -12.24% -97.85% -10.82%

Do analysts rate ARAY or KEQU?

Accuray currently has a consensus price target of $2.00, suggesting a potential upside of 651.88%. Given Accuray's higher possible upside, research analysts clearly believe Accuray is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Accuray 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor ARAY or KEQU?

In the previous week, Accuray and Accuray both had 1 articles in the media. Kewaunee Scientific's average media sentiment score of 1.05 beat Accuray's score of 0.68 indicating that Kewaunee Scientific is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kewaunee Scientific 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MBOT or ARAY?

In the previous week, Microbot Medical and Microbot Medical both had 1 articles in the media. Microbot Medical's average media sentiment score of 1.02 beat Accuray's score of 0.68 indicating that Microbot Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accuray 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ARAY or LUNG?

Accuray has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Accuray $401.95M 0.08 -$49.19M -$0.40 N/A Pulmonx $90.50M 1.07 -$54M -$1.16 N/A

Is ARAY or LUNG more profitable?

Accuray has a net margin of -12.24% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat Accuray's return on equity. Company Net Margins Return on Equity Return on Assets Accuray -12.24% -97.85% -10.82% Pulmonx -55.03% -96.66% -38.32%

Does the media prefer ARAY or LUNG?

In the previous week, Pulmonx had 11 more articles in the media than Accuray. MarketBeat recorded 12 mentions for Pulmonx and 1 mentions for Accuray. Pulmonx's average media sentiment score of 0.91 beat Accuray's score of 0.68 indicating that Pulmonx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Accuray 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulmonx 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Accuray (ARAY) Competitors

$0.27 +0.01 (+2.31%)

As of 09/3/2026 04:00 PM Eastern

Compare

ARAY vs. APYX, LNSR, KEQU, MBOT, and LUNG

Should you buy Accuray stock or one of its competitors? Accuray's main competitors and comparable companies include Apyx Medical (APYX), LENSAR (LNSR), Kewaunee Scientific (KEQU), Microbot Medical (MBOT), and Pulmonx (LUNG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Accuray compare to Apyx Medical?

Accuray (NASDAQ:ARAY) and Apyx Medical (NASDAQ:APYX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

64.1% of Accuray shares are owned by institutional investors. Comparatively, 55.3% of Apyx Medical shares are owned by institutional investors. 2.4% of Accuray shares are owned by company insiders. Comparatively, 15.9% of Apyx Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Accuray has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

Apyx Medical has lower revenue, but higher earnings than Accuray. Apyx Medical is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$401.95M	0.08	-$49.19M	-$0.40	N/A
Apyx Medical	$52.84M	2.44	-$11.21M	-$0.20	N/A

Accuray presently has a consensus target price of $2.00, suggesting a potential upside of 651.88%. Apyx Medical has a consensus target price of $6.60, suggesting a potential upside of 115.69%. Given Accuray's higher possible upside, analysts clearly believe Accuray is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Accuray has a net margin of -12.24% compared to Apyx Medical's net margin of -14.78%. Apyx Medical's return on equity of -76.60% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-12.24%	-97.85%	-10.82%
Apyx Medical	-14.78%	-76.60%	-13.91%

In the previous week, Apyx Medical had 2 more articles in the media than Accuray. MarketBeat recorded 3 mentions for Apyx Medical and 1 mentions for Accuray. Apyx Medical's average media sentiment score of 0.85 beat Accuray's score of 0.68 indicating that Apyx Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apyx Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Apyx Medical beats Accuray on 10 of the 17 factors compared between the two stocks.

How does Accuray compare to LENSAR?

LENSAR (NASDAQ:LNSR) and Accuray (NASDAQ:ARAY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

LENSAR has a net margin of 57.57% compared to Accuray's net margin of -12.24%. Accuray's return on equity of -97.85% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
Accuray	-12.24%	-97.85%	-10.82%

In the previous week, Accuray had 1 more articles in the media than LENSAR. MarketBeat recorded 1 mentions for Accuray and 0 mentions for LENSAR. Accuray's average media sentiment score of 0.68 beat LENSAR's score of 0.00 indicating that Accuray is being referred to more favorably in the news media.

Company	Overall Sentiment
LENSAR	Neutral
Accuray	Positive

LENSAR currently has a consensus target price of $11.50, indicating a potential upside of 39.39%. Accuray has a consensus target price of $2.00, indicating a potential upside of 651.88%. Given Accuray's higher probable upside, analysts clearly believe Accuray is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

LENSAR has higher earnings, but lower revenue than Accuray. LENSAR is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.73	-$34.28M	-$0.33	N/A
Accuray	$401.95M	0.08	-$49.19M	-$0.40	N/A

LENSAR has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Accuray has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 2.4% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

LENSAR and Accuray tied by winning 8 of the 16 factors compared between the two stocks.

How does Accuray compare to Kewaunee Scientific?

Accuray (NASDAQ:ARAY) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Kewaunee Scientific has a net margin of 3.41% compared to Accuray's net margin of -12.24%. Kewaunee Scientific's return on equity of 14.10% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-12.24%	-97.85%	-10.82%
Kewaunee Scientific	3.41%	14.10%	5.55%

In the previous week, Accuray and Accuray both had 1 articles in the media. Kewaunee Scientific's average media sentiment score of 1.05 beat Accuray's score of 0.68 indicating that Kewaunee Scientific is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kewaunee Scientific	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Accuray has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market. Comparatively, Kewaunee Scientific has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Kewaunee Scientific has lower revenue, but higher earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$401.95M	0.08	-$49.19M	-$0.40	N/A
Kewaunee Scientific	$282M	0.37	$9.62M	$3.22	11.43

Accuray currently has a consensus price target of $2.00, suggesting a potential upside of 651.88%. Given Accuray's higher possible upside, research analysts clearly believe Accuray is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

64.1% of Accuray shares are owned by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are owned by institutional investors. 2.4% of Accuray shares are owned by company insiders. Comparatively, 14.1% of Kewaunee Scientific shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Kewaunee Scientific beats Accuray on 10 of the 14 factors compared between the two stocks.

How does Accuray compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and Accuray (NASDAQ:ARAY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by company insiders. Comparatively, 2.4% of Accuray shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Microbot Medical has higher earnings, but lower revenue than Accuray. Microbot Medical is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.24	N/A
Accuray	$401.95M	0.08	-$49.19M	-$0.40	N/A

Microbot Medical presently has a consensus price target of $6.38, suggesting a potential upside of 342.71%. Accuray has a consensus price target of $2.00, suggesting a potential upside of 651.88%. Given Accuray's higher possible upside, analysts plainly believe Accuray is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Microbot Medical has a net margin of 0.00% compared to Accuray's net margin of -12.24%. Microbot Medical's return on equity of -21.87% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.87%	-20.76%
Accuray	-12.24%	-97.85%	-10.82%

In the previous week, Microbot Medical and Microbot Medical both had 1 articles in the media. Microbot Medical's average media sentiment score of 1.02 beat Accuray's score of 0.68 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Microbot Medical has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Accuray has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Summary

Microbot Medical beats Accuray on 8 of the 14 factors compared between the two stocks.

How does Accuray compare to Pulmonx?

Accuray (NASDAQ:ARAY) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Accuray currently has a consensus target price of $2.00, indicating a potential upside of 651.88%. Pulmonx has a consensus target price of $7.67, indicating a potential upside of 239.23%. Given Accuray's higher possible upside, research analysts clearly believe Accuray is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accuray	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

64.1% of Accuray shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 2.4% of Accuray shares are owned by company insiders. Comparatively, 7.5% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Accuray has a net margin of -12.24% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat Accuray's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accuray	-12.24%	-97.85%	-10.82%
Pulmonx	-55.03%	-96.66%	-38.32%

Accuray has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

In the previous week, Pulmonx had 11 more articles in the media than Accuray. MarketBeat recorded 12 mentions for Pulmonx and 1 mentions for Accuray. Pulmonx's average media sentiment score of 0.91 beat Accuray's score of 0.68 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accuray	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmonx	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Accuray has higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Accuray, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accuray	$401.95M	0.08	-$49.19M	-$0.40	N/A
Pulmonx	$90.50M	1.07	-$54M	-$1.16	N/A

Summary

Accuray and Pulmonx tied by winning 8 of the 16 factors compared between the two stocks.

Get Accuray News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARAY vs. The Competition

Export

Metric	Accuray	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.05M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-0.66	25.93	273.28	25.38
Price / Sales	0.08	73.29	613.48	92.60
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	0.76	6.04	12.89	6.14
Net Income	-$49.19M	$150.03M	$3.47B	$349.01M
7 Day Performance	-2.88%	-1.30%	0.61%	-0.27%
1 Month Performance	-14.52%	1.29%	5.73%	0.68%
1 Year Performance	-82.38%	9.89%	25.37%	14.84%

Accuray Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARAY Accuray	2.6947 of 5 stars	$0.27 +2.3%	$2.00 +651.9%	-81.8%	$31.05M	$401.95M	N/A	1,040	Analyst Downgrade
APYX Apyx Medical	3.0469 of 5 stars	$3.17 +2.8%	$6.60 +108.4%	+61.1%	$134.57M	$52.84M	N/A	270
LNSR LENSAR	2.2336 of 5 stars	$9.17 -0.7%	$11.50 +25.4%	-31.5%	$112.53M	$58.44M	N/A	110	Positive News
KEQU Kewaunee Scientific	1.2622 of 5 stars	$36.59 -1.8%	N/A	-32.7%	$105.01M	$282M	11.36	1,231	Positive News Upcoming Earnings
MBOT Microbot Medical	2.7202 of 5 stars	$1.49 +0.3%	$6.38 +329.3%	-59.3%	$100.08M	$346K	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARAY) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accuray (ARAY) Competitors

ARAY vs. APYX, LNSR, KEQU, MBOT, and LUNG

How does Accuray compare to Apyx Medical?

Summary

How does Accuray compare to LENSAR?

Summary

How does Accuray compare to Kewaunee Scientific?

Summary

How does Accuray compare to Microbot Medical?

Summary

How does Accuray compare to Pulmonx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAY vs. The Competition

Accuray Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Accuray (ARAY) Competitors

ARAY vs. APYX, LNSR, KEQU, MBOT, and LUNG

How does Accuray compare to Apyx Medical?

Do institutionals and insiders hold more shares of ARAY or APYX?

Which has more volatility & risk, ARAY or APYX?

Which has higher valuation and earnings, ARAY or APYX?

Do analysts prefer ARAY or APYX?

Is ARAY or APYX more profitable?

Does the media prefer ARAY or APYX?

Summary

How does Accuray compare to LENSAR?

Is LNSR or ARAY more profitable?

Does the media refer more to LNSR or ARAY?

Do analysts rate LNSR or ARAY?

Which has higher earnings and valuation, LNSR or ARAY?

Which has more risk & volatility, LNSR or ARAY?

Do insiders & institutionals believe in LNSR or ARAY?

Summary

How does Accuray compare to Kewaunee Scientific?

Is ARAY or KEQU more profitable?

Does the media favor ARAY or KEQU?

Which has more risk and volatility, ARAY or KEQU?

Which has higher earnings and valuation, ARAY or KEQU?

Do analysts rate ARAY or KEQU?

Do institutionals and insiders hold more shares of ARAY or KEQU?

Summary

How does Accuray compare to Microbot Medical?

Do insiders & institutionals have more ownership in MBOT or ARAY?

Which has stronger earnings & valuation, MBOT or ARAY?

Do analysts prefer MBOT or ARAY?

Is MBOT or ARAY more profitable?

Does the media refer more to MBOT or ARAY?

Which has more volatility & risk, MBOT or ARAY?

Summary

How does Accuray compare to Pulmonx?

Do analysts rate ARAY or LUNG?

Do insiders and institutionals believe in ARAY or LUNG?

Is ARAY or LUNG more profitable?

Which has more volatility & risk, ARAY or LUNG?

Does the media prefer ARAY or LUNG?

Which has preferable earnings and valuation, ARAY or LUNG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARAY vs. The Competition

Accuray Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools